What Limits Filter Load Capacity During Sterile Filtration of Dihydrostreptomycin Sulfate Solutions?

Aqueous dihydrostreptomycin sulfate injection compounding begins with a stainless-steel 316L vessel under filtered nitrogen because the bulk API absorbs surface moisture above 60% RH, and residual free water can raise bioburden before aseptic filtration. Where warehouse humidity exceeds 60% RH, closed API containers are pre-conditioned in a dry room at ≤ 40% RH for 24 h before dispensing to reduce caking and electrostatic adhesion to weigh-room surfaces. The sulfate salt is dissolved in Water for Injection at 20–25°C using low-shear agitation at 80–120 rpm; concentration is stated as dihydrostreptomycin base equivalents, with common pilot-batch targets of 200–250 mg base/mL, although published data for every regional marketed strength is limited. Dissolution is followed by pH adjustment using 0.1 N sulfuric acid or 0.1 N sodium hydroxide to a final pH of 4.5–6.5, and tonicity is adjusted with sodium chloride or dextrose to 280–320 mOsm/kg because hypertonic injections increase intramuscular irritation in cattle and swine. Pre-filtration conditioning uses a 0.45 µm polypropylene depth filter to reduce particle load, followed by a sterilising-grade 0.22 µm polyethersulfone membrane; maximum differential pressure is maintained below 1.0 bar because the sulfate salt can form a low-permeability surface cake that reduces flux under high shear. The filled solution is aseptically transferred into sterile Type I borosilicate vials of 50 mL, 100 mL, or 250 mL nominal fill volume, with chlorobutyl rubber stoppers and aluminium flip-off seals. In-process checks include osmolality by freezing-point depression, pH with a calibrated electrode, and particulate matter counts according to USP <788>; final release includes sterility testing per Ph. Eur. 2.6.1 and bacterial endotoxins per USP <85>. Because published data on terminal moist-heat sterilisation of this specific API is limited, aseptic filtration per EU GMP Annex 1 remains the default manufacturing route. The injection solution is incompatible with strong oxidising agents and with highly alkaline cleaning residues; sodium hypochlorite tank sanitisers are rinsed to below detection before use because aminoglycoside degradation can occur under oxidative stress.

Evaluating Compression Behaviour of Dihydrostreptomycin Sulfate Tablet Blends at Industrial Press Speeds

Because dihydrostreptomycin sulfate is hygroscopic and frequently supplied as a fine powder with poor direct-compaction flow, wet granulation is selected for veterinary tablets intended for oral administration to pre-ruminant calves and lambs where enteric infections require high-dose single-unit accuracy. An intragranular charge of API at 40–60% w/w is combined with microcrystalline cellulose PH101 at 20–30% w/w, lactose monohydrate 200M as diluent, crospovidone at 3% w/w, and povidone K30 at 3% w/w dissolved in purified water as binder. Wet massing is performed in a 300 L high-shear mixer with impeller speed 150 rpm and chopper speed 1500 rpm; the endpoint is defined by an impeller torque increase of 15–20% above dry-mix baseline, not by fixed granulation time alone. The granulate is dried in a fluid-bed dryer with inlet air at 55–60°C until loss on drying reaches 1.5–2.5% w/w, then milled through a 0.8 mm conical screen at 2000 rpm. Final blending with sodium starch glycolate at 2% w/w, talc at 1% w/w, and magnesium stearate at 0.5% w/w is performed in a bin blender at 8–12 rpm for 15 min. Compression is carried out on a 27-station rotary tablet press with 9 mm round B-tooling at 25–45 rpm; main compression force is maintained between 8 kN and 12 kN. The resulting tablets typically meet hardness 8–12 kp, thickness 3.4–3.8 mm, friability not more than 0.8% w/w per USP <1216>, and disintegration not more than 15 min in 0.1 N HCl at 37 ± 1°C per USP <701>. Uniformity of dosage units is checked per USP <905> with an acceptance value ≤ 15.0. Because the API sorbs moisture above 60% RH, immediate packaging uses cold-form aluminium/aluminium blisters or HDPE bottles with a 33 mm child-resistant closure and induction seal, each containing a 1 g silica gel desiccant canister when filled in non-climate-controlled packing halls.

Encapsulation of dihydrostreptomycin sulfate into hard-shell capsules is applied where oral administration requires taste masking of the bitter sulfate salt and where the API load is high enough to avoid a separate granulation step. The powder blend for immediate-release capsules contains API at 30–50% w/w, lactose monohydrate 200M or mannitol as filler, croscarmellose sodium at 2% w/w as disintegrant, colloidal silicon dioxide at 0.5% w/w as flow aid, and magnesium stearate at 0.5% w/w as lubricant. Filling is performed on a continuous-motion tamping-pin capsule machine at 30,000–60,000 capsules/h using size 3 or size 2 hard gelatin or HPMC capsules; fill weight is controlled to ± 5% of target by automatic checkweighing and periodic destructive weight verification. The capsule blend is prepared in a room held at ≤ 40% RH and 20–25°C because pre-drying is required when ambient humidity exceeds 60% RH; without desiccation, the bulk powder absorbs enough moisture to cause picking on capsule sealing pins and softening at the body-cap junction. Dissolution testing is performed according to USP <711> using Apparatus II at 50 rpm in 900 mL of 0.1 N HCl at 37 ± 0.5°C, with a typical immediate-release criterion of not less than 80% release at 45 min; published data for this specific capsule formulation is limited, so the criterion must be verified against the target-market dossier. Capsule shells are packaged in 40 cc or 75 cc HDPE bottles with 33 mm child-resistant caps and induction seals, with a 1 g desiccant unit placed inside each bottle. Unprotected blister packaging is avoided because moisture ingress through standard PVC/PE/Aclar laminates at tropical warehouse conditions above 30°C and 75% RH can soften the capsule shell and reduce assay of the hygroscopic API over storage.

Reconstituted Oral Powder Dosing Accuracy and Water Hardness Interference

In drinking-water mass medication for pigs and poultry, the critical process variable is not dry blending uniformity alone but accuracy of reconstitution under variable farm water quality. A water-soluble oral powder is formulated with dihydrostreptomycin sulfate at 10–20% w/w, dextrose monohydrate or lactose as diluent, anhydrous citric acid and trisodium citrate dihydrate as buffering salts to target a reconstituted pH of 4.0–5.5, and colloidal silicon dioxide at 0.5% w/w to reduce caking in bulk storage. The powder is dry-blended in a 300 kg ribbon blender or V-blender at 12 rpm for 15 min, with sampling at 10 points and assay RSD not more than 5.0%; if RSD exceeds this limit, blending time is extended in 5 min increments rather than increasing speed, because the API particle-size distribution tends to segregate under high shear. Typical farm dilution is 0.5–1.0 g active base per litre of final drinking water, administered over 4–8 h each day; stock solutions are prepared at 10–20 g/L in a separate mixing tank before inline proportioner metering at 1:100 or 1:200. Water hardness up to 300 ppm CaCO₃ does not precipitate the sulfate salt at these concentrations, but water pH above 8.0 and free residual chlorine above 2 ppm reduce potency on standing, and published data on the extent of degradation in specific farm water matrices is limited. Stock solutions should therefore be used within 24 h and protected from light. The finished powder is packed in 1 kg or 5 kg foil-lined pouches with an oxygen absorber; after opening, the product is used within 48 h under high-humidity farm conditions to avoid caking and water uptake.

Fluid-bed granulation of dihydrostreptomycin sulfate into 5–10% w/w active granules is selected to cut respirable dust and reduce cross-contamination when operators top-dress open feed in calf or piglet pens. The granule matrix combines the API with dicalcium phosphate dihydrate or corn starch and is sprayed with an aqueous binder solution of hypromellose at 5% w/w; spray rate in a 120 kg top-spray fluid-bed granulator is held at 150–250 g/min, inlet air at 60–65°C, outlet air at 35–40°C, and atomising air at 1.0–1.5 bar. Once the target particle size of 150–500 µm is reached, the product is dried to a moisture content of 1.0–2.0% w/w and screened through a 710 µm safety sieve. Fines below 75 µm are limited to ≤ 10% w/w to suppress airborne dust; if the top-spray process produces excess fines, an additional aqueous binder spray of 2–3% w/w is applied after the first drying step rather than increasing binder concentration, because higher polymer content slows release in the gut. Bulk density is controlled to 0.55–0.70 g/mL and water activity below 0.60 to prevent caking during farm storage. The granulated product is filled into 25 kg polyethylene bags inside fibreglass drums or 1 kg foil sachets, and the labelled use rate for top-dressing is 0.5–1.0 kg granular product per tonne of feed mixed uniformly in a horizontal feed mixer for 10 min. Content uniformity is verified by sampling 10 locations per tonne, with the active assay RSD not more than 3.0%; if the granule particle-size distribution drifts during a batch, mixing time is adjusted rather than relying on over-mixing, which can break friable granules and regenerate dust.

When Dihydrostreptomycin Sulfate Premix Is Pelleted Above 70°C

In-feed premixes containing dihydrostreptomycin sulfate are prepared on carriers such as ground corn cobs, wheat middlings, or calcium carbonate at active concentrations between 1% w/w and 10% w/w; the final feed inclusion rate is set by national authorisation and is commonly expressed in grams of active base per tonne of complete feed. Premix homogeneity is tested by taking 10 samples across a 500 kg ribbon mixer after 15 min and assaying for RSD ≤ 5.0%; because carrier density and oil-holding capacity influence segregation, the carrier lot is characterised for bulk density and particle size 150–800 µm before blending. Steam conditioning at 70–90°C during pelleting creates the main process risk: dihydrostreptomycin sulfate is not highly labile under dry heat, but moist heat above 80°C can accelerate degradation when the carrier contains free alkaline compounds, and published data for this specific premix configuration is limited; therefore a pilot-scale pelleting recovery study is required before commercial production. Pellet die outlet temperature should be kept below 70°C subject to recovery data, and post-pellet retention time in a counterflow cooler is kept below 15 min. Alkaline carriers such as magnesite are avoided because alkaline moisture accelerates degradation; if ground limestone is used, free moisture is held below 2% w/w. Carryover into non-medicated feed is controlled by sequencing flush batches of 50 kg ground corn or wheat bran after each medicated run; the next non-medicated batch is assayed to ensure residual dihydrostreptomycin is below 1% of the labelled active concentration to avoid violative tissue residues. The following table lists EU maximum residue limits for dihydrostreptomycin under EU Regulation (EU) No 37/2010; these MRL values are not inclusion rates and do not replace product-specific withdrawal periods.

Aqueous non-sterile oral solutions of dihydrostreptomycin sulfate are prepared for direct drench administration in neonatal calves, lambs, and piglets where enteric concentrations are the primary therapeutic target and systemic absorption is secondary. The solution base consists of purified water, dihydrostreptomycin sulfate equivalent to 100–250 mg base/mL, citric acid or acetate buffer to hold pH at 5.0–6.0, and potassium sorbate at 0.1–0.2% w/v or sodium benzoate at 0.1% w/v as preservative; sorbitol solution at 20% w/v is included to reduce the bitter aftertaste and improve repeated-dose acceptance. Mixing is carried out in a 316L stainless-steel vessel at 20–25°C for 15 min at 100 rpm, followed by filtration through a 5 µm polypropylene cartridge before filling into 100 mL, 250 mL, or 1 L HDPE bottles fitted with a measuring chamber or a 16-gauge oral dosing gun adapter. The specification includes viscosity below 10 mPa·s at 20°C and fill volume tolerance ± 5%; low viscosity is critical because high-viscosity vehicles can clog automatic drenching equipment and produce variable dose volume in fast-moving livestock handling lines. Light exposure accelerates discoloration, so the HDPE bottle contains an amber pigment or is stored in a closed carton; storage is below 25°C, and in-use shelf life after first opening is limited to 28 days. During stability evaluation, samples are stored at 25 ± 2°C and 60% RH and at 40 ± 2°C and 75% RH for accelerated screening, with assay, pH, preservative content, and appearance monitored at 0, 1, 3, and 6 months; published data on this specific shelf-life assignment is limited and must be confirmed with commercial-scale batches under the target-market climate zone. The solution is incompatible with strong oxidising agents, and sodium hypochlorite sanitising residues in mixing tanks must be rinsed below detection before use because hypochlorite degrades the aminoglycoside.